Last reviewed · How we verify
Intensified Thiazide Treatment Group
Intensified thiazide treatment lowers blood pressure by increasing urinary sodium and water excretion through inhibition of sodium-chloride cotransport in the distal convoluted tubule.
Intensified thiazide treatment lowers blood pressure by increasing urinary sodium and water excretion through inhibition of sodium-chloride cotransport in the distal convoluted tubule. Used for Hypertension (resistant or difficult-to-control).
At a glance
| Generic name | Intensified Thiazide Treatment Group |
|---|---|
| Sponsor | Cedars-Sinai Medical Center |
| Drug class | Thiazide diuretic |
| Target | Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Thiazide diuretics block the sodium-chloride symporter (NCC) in the kidney's distal convoluted tubule, reducing intravascular volume and peripheral vascular resistance. This intensified treatment regimen uses higher doses or more frequent dosing of thiazide agents to achieve greater antihypertensive efficacy in resistant or difficult-to-control hypertension.
Approved indications
- Hypertension (resistant or difficult-to-control)
Common side effects
- Hypokalemia
- Hyponatremia
- Hyperglycemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Metabolic alkalosis
Key clinical trials
- Treating Nocturnal Hypertension and Nocturia in African American Men (PHASE4)
- Nephropathy In Type 2 Diabetes and Cardio-renal Events (PHASE4)
- Protocolized Diuretic Strategy in Cardiorenal Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: